Inequality and heterogeneity in health-related quality of life: findings based on a large sample of cross-sectional EQ-5D-5L data from the Swedish general population.


Journal

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation
ISSN: 1573-2649
Titre abrégé: Qual Life Res
Pays: Netherlands
ID NLM: 9210257

Informations de publication

Date de publication:
Mar 2022
Historique:
accepted: 22 08 2021
pubmed: 11 10 2021
medline: 17 3 2022
entrez: 10 10 2021
Statut: ppublish

Résumé

This study aimed to investigate inequality and heterogeneity in health-related quality of life (HRQoL) and to provide EQ-5D-5L population reference data for Sweden. Based on a large Swedish population-based survey, 25,867 respondents aged 30‒104 years, HRQoL is described by sex, age, education, income, economic activity, health-related behaviours, self-reported diseases and conditions. Results are presented by EQ-5D-5L dimensions, respondents rating of their overall health on the EQ visual analogue scale (EQ VAS), VAS index value and TTO (time trade-off) index value allowing for calculation of quality-adjusted life years (QALYs). Ordinary Least Squares and multivariable logistic regression analyses were used to study inequalities in observed EQ VAS score between socioeconomic groups and the likelihood to report problems on the dimensions, respectively, adjusted for confounders. In total, 896 different health states were reported; 24.1% did not report any problems. Most problems were reported with pain/discomfort. Women reported worse HRQoL than men, and health deteriorated with age. The strongest association between diseases and conditions and EQ VAS score was seen for depression and mental health problems. There was a socioeconomic gradient in HRQoL; adjusting for health-related behaviours, diseases and conditions slightly reduced the differences between educational groups and income groups, but socioeconomic inequalities largely remained. EQ-5D-5L population reference (norms) data are now available for Sweden, including socioeconomic differentials. Results may be used for comparisons with disease-specific populations and in health economic evaluations. The observed socioeconomic inequality in HRQoL should be of great importance for policy makers concerned with equity aspects.

Identifiants

pubmed: 34628587
doi: 10.1007/s11136-021-02982-3
pii: 10.1007/s11136-021-02982-3
pmc: PMC8921093
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

697-712

Informations de copyright

© 2021. The Author(s).

Références

Soc Sci Med. 2016 Sep;165:66-74
pubmed: 27497260
J Intern Med. 2015 Jan;277(1):94-136
pubmed: 25174800
Health Econ. 2005 Aug;14(8):831-50
pubmed: 15712264
Qual Life Res. 2011 Dec;20(10):1727-36
pubmed: 21479777
Soc Sci Med. 1991;33(5):545-57
pubmed: 1962226
PLoS One. 2019 Apr 29;14(4):e0214283
pubmed: 31034491
Qual Life Res. 2018 Nov;27(11):2859-2871
pubmed: 30196340
HRB Open Res. 2018 Sep 4;1:22
pubmed: 32002510
Health Econ. 2003 Aug;12(8):637-54
pubmed: 12898662
PLoS One. 2018 May 11;13(5):e0197098
pubmed: 29750806
Pharmacoeconomics. 2020 Aug;38(8):839-856
pubmed: 32307663
Qual Life Res. 2021 Mar;30(3):831-840
pubmed: 33237551
Med Decis Making. 2016 Jan;36(1):8-19
pubmed: 25908564
Health Qual Life Outcomes. 2020 Oct 7;18(1):333
pubmed: 33028345
Value Health. 2009 Mar;12 Suppl 1:S5-9
pubmed: 19250132
Int J Environ Res Public Health. 2017 Apr 16;14(4):
pubmed: 28420153
J Urban Health. 2009 Jul;86(4):551-61
pubmed: 19283489
Value Health. 2015 Jul;18(5):655-62
pubmed: 26297094
Qual Life Res. 2016 May;25(5):1313-21
pubmed: 26482825
Qual Life Res. 2014 Mar;23(2):443-7
pubmed: 23921597
Qual Life Res. 2016 Feb;25(2):323-333
pubmed: 26242249
Health Qual Life Outcomes. 2016 Sep 20;14(1):133
pubmed: 27644755
Int J Med Inform. 2019 Sep;129:404-412
pubmed: 31445284
JMIR Res Protoc. 2021 Jan 11;10(1):e21727
pubmed: 33427685
Int J Environ Res Public Health. 2016 Mar 21;13(3):
pubmed: 27007387
Soc Sci Med. 1997 Mar;44(6):901-10
pubmed: 9080570
Eur J Epidemiol. 2019 Apr;34(4):423-437
pubmed: 30929112
Eur J Health Econ. 2019 Aug;20(6):933-944
pubmed: 31030292
Qual Life Res. 2021 Mar;30(3):803-816
pubmed: 33025373
Lancet. 2008 Nov 8;372(9650):1661-9
pubmed: 18994664
Value Health. 2020 Feb;23(2):251-259
pubmed: 32113631
Qual Life Res. 2021 Nov;30(11):3127-3144
pubmed: 33387290
Health Qual Life Outcomes. 2018 Nov 8;16(1):210
pubmed: 30409137
Eur J Health Econ. 2020 Nov;21(8):1169-1178
pubmed: 32813084
Qual Life Res. 2018 Sep;27(9):2337-2348
pubmed: 29767329
Health Qual Life Outcomes. 2014 May 16;12:74
pubmed: 24885017
Qual Life Res. 2001;10(7):621-35
pubmed: 11822795
Qual Life Res. 2020 Jun;29(6):1465-1482
pubmed: 32016683

Auteurs

Fitsum Sebsibe Teni (FS)

Health Outcomes and Economic Evaluation Research Group, Stockholm Centre for Healthcare Ethics, Department of Learning, Informatics, Management and Ethics, Karolinska Institutet, Tomtebodavägen 18a, 171 77, Stockholm, Sweden.

Ulf-G Gerdtham (UG)

Department of Economics, Lund University, Lund, Sweden.
Health Economics Unit, Department of Clinical Sciences in Malmö, Lund University, Lund, Sweden.

Reiner Leidl (R)

Institute for Health Economics and Health Care Management, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany.
Munich Center of Health Sciences, Ludwig-Maximilians University, Munich, Germany.

Martin Henriksson (M)

Center for Medical Technology Assessment, Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden.

Mimmi Åström (M)

Health Outcomes and Economic Evaluation Research Group, Stockholm Centre for Healthcare Ethics, Department of Learning, Informatics, Management and Ethics, Karolinska Institutet, Tomtebodavägen 18a, 171 77, Stockholm, Sweden.
Equity and Health Policy Research Group, Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden.

Sun Sun (S)

Health Outcomes and Economic Evaluation Research Group, Stockholm Centre for Healthcare Ethics, Department of Learning, Informatics, Management and Ethics, Karolinska Institutet, Tomtebodavägen 18a, 171 77, Stockholm, Sweden.
Department of Epidemiology and Global Health, Umeå University, Umeå, Sweden.

Kristina Burström (K)

Health Outcomes and Economic Evaluation Research Group, Stockholm Centre for Healthcare Ethics, Department of Learning, Informatics, Management and Ethics, Karolinska Institutet, Tomtebodavägen 18a, 171 77, Stockholm, Sweden. kristina.burstrom@ki.se.
Equity and Health Policy Research Group, Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden. kristina.burstrom@ki.se.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH